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Chronic lymphocytic leukemia (CLL) is a malignancy of mature
B-lymphocytes that manifests in a variety of clinical courses.
The accumulation of CLL-cells is primarily caused by defective
apoptosis; however, a higher proliferative capacity has also
been found to correlate with poorer prognostic factors.
Proliferating CLL-cells are confined to specialized structures
called pseudofollicles, which contain CLL-cells, T-lympho-
cytes, and stromal cells. We established an in vitro model for
pseudofollicles to characterize the behavior of CLL-cells in
relation to clinical courses with different outcomes. Only CLL-
cells from progressive clinical cases were inducible to pro-
liferate by a combination of soluble CD40L/IL-2/IL-10 in
co-culture with stromal cells. Proliferating CLL-cells showed a
higher and more extensive expression of antigens, which are
important in T–B-cell interactions such as CD40, MHC II, and
adhesion molecules. IL-4 increased interferon regulatory factor-
4 expression and induced a specific immunophenotype, which
may imply plasmacytic differentiation. Furthermore, it was
shown that co-cultured stromal cells protected CLL-cells from
apoptosis. CLL-cells from clinically indolent cases had a far
worse survival rate in medium than the cells from poor
prognostic cases. Thus, we can assume that not only a different
resistance to apoptosis, but also proliferation contributes to the
progression of CLL resulting in bone marrow failure with
thrombocytopenia and anemia.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the
accumulation of monoclonal, resting B-lymphocytes expressing
a typical pattern of antigens.1
Despite the similar cytology and immunophenotype, CLL
manifests itself in a variety of different clinical courses. The
disease burden based on clinical staging systems (e.g. RAI stage
III: anemia, or IV: thrombocytopenia) is the most significant
prognostic factor for survival.2 The poor prognostic impact of
the germ line immunoglobulin heavy chain variable region
(IgVH) gene,
2 zeta-chain-associated protein kinase (ZAP-70)
expression,3 and CD38 expression4 were confirmed at an early
stage of the disease.
The progressive increase in lymphocyte counts despite low
mitotic rates of dividing cells led to the concept that CLL is
primarily attributable to defective apoptosis.5 A proliferating
pool, however, has been identified in so-called proliferation
centers or pseudo-follicles (PC), composed of cycling CLL-cells
(Ki-67þ , Survivinþ , p27, Bcl-2þ , CD23hi), delicate stromal
cell networks and activated (CD40Lþ ) TH-cells.
6–9 The trans-
cription factor interferon regulatory factor-4 (IRF4 [multiple
myeloma oncogen 1(MUM1)]) can also be differentially
expressed in proliferation centers compared with the surrounding
lymphocytes.10
Evidences from a number of in vitro experiments with CD40L
and T-cell-derived cytokines indicate the importance of
T-lymphocytes in CLL but conflicting results were published
concerning CD40 and IL-4 with regard to CLL-cell proliferation-
induction and anti-apoptotic effects.7,11–15 CD40 activation
combined with IL-2 and IL-10 was found to synergize in
proliferation induction in CLL.16 IL-4 normally induces IgE class
switching and additional IL-10 enhances IgE production by
promoting in vitro plasma cell differentiation.17
Recent experiments revealed a different proliferative capacity
in CLL: in vivo measurements showed that a higher birth rate of
CLL-cells correlates with disease progression.18 Unmethylated
CpG motif containing oligodeoxynucleotide (CpG-ODN)
stimulated CLL-cells of patients with a worse prognosis through
Akt-mTOR (mammalian target of rapamycin) pathway to
proliferate more often in vitro.19 The higher LDH level found
in CLL with ‘poor prognostic cytogenetics’ as described by
Jahrsdo¨rfer et al.20 also refers to the significance of CLL-cell
neogenesis in disease progression.
Despite an obvious long half-life in vivo, CLL-cells die fast
in vitro during a short-term culture in medium.21 Co-cultures
either with human bone marrow-derived stromal cells (BMSCs)
or even with mouse fibroblasts significantly reduced the
percentage of apoptotic CLL-cells.13,22
The aim of this study was to establish an in vitro cell culture
system similar to proliferation centers to investigate the
differences in the behavior of CLL-cells in relation to prognostic
and clinical features. Our experiments indicate that only
CLL-cells from progressive cases usually presenting with
thrombocytopenia were able to proliferate on T-cell-derived
cytokine stimulation in co-culture with BMSCs. We could show
that CLL-cells had different survival capacities in medium with a
correlation to prognostic factors. Furthermore, T-cell-derived cyto-
kines exerted characteristic effects on the immunophenotype
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and gene expression of CLL-cells. These data confirm the
concept of the heterogeneity of CLLs and the role of the
microenvironment in the pathophysiology of this disease.
Materials and methods
Patients
Recruitment of 21 CLL patients, 7 women and 14 men, with
median age of 65 (39–84) years was approved by the ethics
committee of the University of Regensburg. All participants gave
written informed consent. The diagnoses were based on
standard clinical immunophenotyping and cytology. The
patients were either untreated or had not been treated in the
previous 3 months. Table 1 summarizes the main clinical data of
the patients, whereas the therapy states of the treated patients
are listed in Supplementary Table 4.
Preparation of BM mesenchymal stromal cell (BMSC)
cultures
Ten different bone marrow aspirates, taken for routine diag-
nostic procedures, were applied for BMSC cultures. Specimens
were chosen exclusively from untreated lymphoma or ITP
patients without detectable abnormal cells. Therefore, we
always applied allogenous BMSCs. Primary human BMSC
cultures were established as described earlier,22 and details
are shown in the Supplementary information at Leukemia’s
website.
Homogeneity of BMSCs was proved by the investigation of
adhesion molecule expressions (ICAM1, VCAM1) and cytokine
secretions (IL-6, IL-8, SDF-1) (data not shown).
Separation of CLL-cells from peripheral blood
Peripheral blood mononuclear cells were isolated by Ficoll-
Hypaque technique with Biocoll (Biochrom, Berlin, Germany).
For separation of CLL-cells, surface staining of the isolated
peripheral blood mononuclear cells was performed with four
monoclonal antibodies: fluorescein isothiocyanate-labeled anti-
glycophorin A, phycoerytrin-labeled anti-CD14, anti-CD56, and
allophycocyanin-labeled anti-CD3. The unstained cells in the
lymphoid gate were sorted by a FACSAria cell sorter (BD
Biosciences, Heidelberg, Germany). The prepared cell popula-
tions contained usually 498% CLL-cells, assessed by direct
immunofluorescence staining using a FACSCanto flow cyt-
ometer (BD Biosciences). Source and specificity of the applied
monoclonal antibodies are listed in Supplementary Table 1,
shown in the Supplementary information at Leukemia’s website.
Staining specificity was verified by respective isotype controls
(BD Biosciences).
Culture conditions
106 purified CLL-cells/0.5 ml/well were cultured in DMEM (PAN
Biotech GmbH, Aidenbach, Germany) supplemented with 10%
FCS. The following co-culture/culture conditions were applied:
(1) BMSCs; (2) BMSCs and soluble CD40 ligand (sCD40L); (3)
BMSCs, sCD40L, and IL-4; (4) BMSCs, sCD40L, IL-2, and IL-10;
(5) only medium; (6) medium and sCD40L; (7) medium,
sCD40L, and IL-4; and (8) medium, sCD40L, IL-2, and IL-10.
The CLL-cells were harvested after 84 h and further analyzed
without sorting again.
The applied BMSCs were entirely developed and showed no
morphological sign of development into macrophages or fat
cells during the co-culture (data not shown).
The human recombinant reagents listed above were used
as follows: CD40L: 1mg/ml (PeproTech EC, Hamburg, Germany
or R&D Systems, Wiesbaden-Nordenstadt, Germany), IL-4:
10 ng/ml, IL-2: 100 U/ml, IL-10: 10 ng/ml (all from PeproTech EC).
Multiparameter flow cytometric DNA analysis
First, surface antigens were stained with fluorochrome-conju-
gated monoclonal antibodies according to the manufacturers’
Table 1 Clinical and prognostic characteristics of the studied patients
Patient Pa/NPb PLTc,
 109/l
HGBd,
g/100ml
Lymphocyte
count,
103/ml
ZAP70
+, %
CD38
+, %
Mutation
state
Mutation
ratio, %
V-gene Age Sex Previous
chemotherapy
Bone marrow
infiltration
20 P 25 6.6 9.4 72 31.2 UMe 0 1–69 66 M Yes 490%
9 P 49 10.1 42.0 70 50.0 UM 0 1–69 73 M Yes 60%
28 P 100 13.7 43.0 53 44.8 UM 1.8 3–23 67 M No 90%
11 P 114 12.4 87.0 41 38.0 UM 0 3–48 57 M No na
23 P 115 11.6 119.0 35 1.6 Mf 12.4 3–7 39 F No na
29 P 115 9.6 63.2 41 2.5 M 4 3–30 78 F Yes na
33 P 140 11.3 65.0 54 32.0 UM 0 3–23 84 M No na
17 P 166 11.5 304.0 83 10.0 UM 0.4 1–2 57 M Yes 60%
13 NP 140 12.9 69.3 6 8.0 NDg ND ND 79 F No na
16 NP 150 12.2 42.6 21 45.0 UM 0 3–33 72 F Yes 77%
19 NP 153 14.3 16.0 37 8.7 UM 0.4 3–30 58 F Yes 80%
21 NP 167 14.5 15.0 32 0.9 UM 0 1–69 55 M No 60%
31 NP 180 13.0 74.0 13 6.6 UM 0 1–69 66 M No na
27 NP 211 15.7 115.7 11 4.1 M 8.0 4–34 64 M No na
30 NP 166 14.1 8.0 8 0.5 M 9.6 1–18 78 M No na
18 NP 171 17.0 20.0 11 4.6 M 9.1 3–30 67 M No 20%
15 NP 185 15.0 15.7 35 5.0 M 7.0 1–69 68 M No 20%
12 NP 200 14.3 40.0 5 18.0 M 5.9 2–5 73 M No na
22 NP 207 14.9 42.8 6 0.3 M 4.5 4–61 46 M No na
32 NP 220 14.4 10.0 13 2.0 ND ND 4–55P 76 F No na
14 NP 223 13.9 38.0 6 10.0 M 5.1 3–53 73 F No na
Notes: aP, cells with inducible proliferation in vitro; bNP, cells without inducible proliferation in vitro; cPLT, count of platelets; dHGB, hemoglobin
concentration; eUM, unmutated; fM, mutated; gND, not determinable; na, not available at the time of the experimental setup.
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data sheets. The applied monoclonal antibodies are listed in
Supplementary Table 1. Red blood cells were lysed and
lymphoid cells were fixed simultaneously by FACS lysing
solution containing 1.5% formaldehyde (BD Biosciences). After
washing, the cells were resuspended in 2% DAPI solution
(Molecular Probes, Eugene, OR) and analyzed on a LSRII flow
cytometer (BD Biosciences). Data acquisition and analysis were
performed using either FACSDiva software (BD Biosciences) or
Wincycle software for cell-cycle analysis (Phoenix Flow
Systems, San Diego, CA).
Antigen expression and cell-cycle distribution were analyzed
within the population of CLL-cells (CD19/CD5 double positive).
Antigen density was expressed in relative fluorescence intensity.
See details in the Supplementary information at Leukemia’s
website.
Flow cytometric analysis of apoptosis
Approximately 5 105 sorted or harvested CLL-cells were
washed in cold PBS and resuspended in 100 ml of annexin-
binding buffer (BD Biosciences) containing 1mg/ml propidium
iodide (PI) (Sigma Aldrich, Taufkirchen, Germany) and 5 ml of
fluorescein isothiocyanate-conjugated annexin V (BD Bio-
sciences). After 15 min incubation period, 400 ml of annexin-
binding buffer were added and the cells were analyzed on a
LSRII flow cytometer using FACSDiva software. Viable cells
were PI- and annexin V-negative.
The detection of DNA fragmentation was performed by DAPI
staining as described above. Apoptotic cells contain less DNA
than living cells and can be detected in the sub-G1 area.
Calculation of cell survival in vitro
Cultured CLL-cells were counted in a Casy Cell Counter Model
DT (electronic pulse area analysis) (innovatis AG CASY
Technology, Reutlingen, Germany) after 84 h in vitro. The living
population was corrected by subtracting the annexin V-positive
fraction from the absolute cell count. We set the number of
preculture live (annexin V-negative) cells to 100%. The
ratio between the corrected living cell number before and after
co-culture resulted in the surviving rate of the CLL-cells under
different culture conditions.
Immunohistochemical staining of IRF4
Immunohistochemistry for IRF4 was performed on formalin-
fixed CLL-cells of cytospin specimens from 12 co-cultured
CLL-cases according to the manufacturers’ data sheets. See
details in the Supplementary information at Leukemia’s website.
Immunofixation
Hydragel (Sebia Inc., Norcross, GA) high-resolution immuno-
fixation technique was applied to detect immunoglobulins and
kappa or lambda free light chains in the culture supernatant.
Immunofixation was carried out with undiluted medium
according to the manufacturer’s recommendations. Serum from
a plasmocytoma patient and polyclonal serum were used as
positive controls.
Gene expression analysis
For gene expression analysis, mRNA was isolated using QIA-
Amp mRNA isolation mini kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s instructions. Firststrand cDNA
synthesis of a total of 2 mg RNA was performed using ImProm-II
reverse transcriptase system (Promega, Mannheim, Germany)
according to the supplier’s recommendations. Gene expression
analyses with TaqMAN gene expression assays (AssayOnDe-
mand, Applied Biosystems, Darmstadt, Germany) were carried
out in a HT-7900 real time PCR machine (Applied Biosystems)
in 384 well plates. Cycling conditions matched the specifica-
tions designed for AssayOnDemand probes by Applied Biosys-
tems. mRNA expression was calculated using the delta–delta
C(t) method of qRT-PCR and quantity is given in arbitrary units
compared with the 18 s gene as housekeeper in all cases.
VH Family assignment
To determine the VH gene family used by the CLL-cells, genomic
DNA was amplified and sequenced. Detailed information about
the applied methods are available as Supplementary information
at Leukemia’s website.
Statistical analysis
Statistical analysis was performed with SPSS, version 16.0.
Graphs denote box and whisker plots. Comparisons of groups of
data were performed using the two-tailed t-test and statistical
significance is considered with P-values p0.05.
Results
CLL-cells change their immunophenotype under the
influence of BMSCs, whereas soluble CD40L exerts only
a marginal effect on antigen expression
CLL-cells up-regulated the majority of the investigated antigens
by the end of the 84 h co-culture with BMSCs. The expression
of activation antigens such as CD23, CD69, co-receptors
HLA-DR, B7-2 (CD86), and adhesion molecules such as ICAM1
(CD54) and CD49d were increased three- to four-fold, whereas
the expression of CD19, CD40, and P-glycoprotein-1 (Pgp-1,
hyaluronate receptor, CD44) increased only 1.5–2-fold
(Figure 1a). The expression of CD45 did not change.
To further characterize the differentiation capacity of co-
cultured CLL-cells, several genes involved in plasma cell
maturation, such as IRF4, a known target for IL-4 and CD40L
in normal B-cells,23 B-cell lineage-specific activator protein
coded by paired box domain 5 (PAX5) critical for B-cell
commitment,24 B-lymphocyte-induced maturation protein-1
(BLIMP1) [PR domain containing 1 (PRDM1)], a transcriptional
repressor of PAX5,25 and Syndecan-1 (SDC1/CD138), a marker
for plasma cells,26 were selected for gene expression analysis.
CLL-cells from peripheral blood strongly expressed PAX5
(Figure 2a) and IRF4 mRNA (Figure 2b), whereas the BLIMP1
expression was very weak (Figure 2c). CD138 mRNA was either
undetectable or expressed at a very low level in the CLL-cells of
the peripheral blood as well as in the cultured CLL-cells (data
not shown).
CLL-cells reduced the expression of both PAX5 and BLIMP1
on BMSCs (Figures 2a and c). IRF4 mRNA levels increased in
most of the cultures with BMSCs, but these changes were not
significant (Figure 2b).
In general, soluble CD40L (sCD40L) slightly altered the
immunophenotype (Figure 1b) and gene expression (Figure 2) of
sorted CLL-cells induced in the co-culture with BMSCs. sCD40L
significantly enhanced the expression intensities of antigens
like CD11c, CD18, CD40, CD54, and HLA-DR and decreased
the expression of CD20 and CD184; however, the range of
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Figure 1 BMSCs and T-cell-derived cytokines (IL-4 and IL-2/IL-10) have marked effects on the immunophenotype of CLL-cells. 106 sorted CLL-
cells per well were cultured on BMSCs with/out different combinations of cytokines; soluble CD40L (1 mg/ml), or sCD40L and IL-4 (10 ng/ml) or
sCD40L and IL-2 (100 U/ml)þ IL-10 (10 ng/ml). The cells were harvested after 84 h and immunophenotyped. (a) Dark gray boxes: antigen
expression before co-culture; black boxes: antigen expression after co-culture with BMSCs. (b) Light gray boxes: antigen expression after co-culture
with BMSCs, white boxes: antigen expression after co-culture with BMSCs and sCD40L. (c) White boxes: antigen expression after co-culture with
BMSCs/sCD40L, fasciated boxes: antigen expression after co-culture with BMSCs/sCD40L and IL-4. (d) White boxes: antigen expression after co-
culture with BMSCs/sCD40L, lengthwise striped boxes: antigen expression after co-culture with BMSCs/sCD40L and IL-2/IL-10. Relative
fluorescence intensities (RFI) of 15–18 independent experiments are depicted as box and whisker plots. Rings indicate outliers and triangles
indicate extreme outliers. Significance (two-tailed) is calculated with the paired t-test with *Pp0.05, **Pp0.001.
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alterations was smaller compared with those induced by BMSCs
(Figures 1a and b).
CLL-cells preserved their differentiation capacity in
response to IL-4
IL-4 stimulation of CLL-cells cultured on BMSCs with sCD40L
dramatically up-regulated several antigens including CD23,
CD40, CD54, and CD86. IL-4 also induced the expression of
HLA-DR and CD18, but decreased CD45, the activation antigen
CD69, the B-cell specific antigens CD19 and CD20, the
adhesion antigens CD11c, CD44, and CD49d, and the
chemokine receptor CD184 (CXCR4). IL-4 did not influence
the expression of CD38 and CD138 (Figure 1c). On the mRNA
level, CD19 was also down-regulated by IL-4 (Figure 2d).
In 10 of 12 investigated cases, IL-4 in combination with
sCD40L and BMSCs significantly increased the expression of
IRF4 mRNA compared with BMSCs with sCD40L (Figure 2b).
To confirm the transcription analysis, immunohistochemistry
was performed for IRF4 expression in trephine biopsy sections
and on cytospins of cultured CLL-cells. IRF4 positive cells were
found in all investigated biopsy sections either forming centers
or being scattered among the surrounding lymphocytes
(Figure 3a). The sorted CLL-cells expressed IRF4 antigen
heterogeneously (Figure 2b). In co-culture with BMSCs
(Figure 3c), BMSCs/sCD40L (Figure 3d), or BMSCs/sCD40L/IL-
2/IL-10 (Figure 3g), IRF4 was obviously not induced. IL-4
exerted a visible effect on IRF4 expression, increasing the
number of strong positive cells and inducing mild expression in
the majority of cells in all investigated specimens (Figure 3e).
Interestingly, the larger cells contained a higher level of IRF4
with strong positivity in their nuclei (Figure 3f).
Expression of PAX5 mRNA (Figure 2a), critical for B-cell
characteristics, was not altered by IL-4 similar to plasma cell
specific genes such as BLIMP1 (Figure 2c) and CD138 (data not
shown). IL-4 induced the expression of IRF4 and decreased
CD19, CD20, and CD45, which may indicate plasma cell
differentiation, although BLIMP1 and CD138 were not induced.
To examine this possibility, the immunoglobulin secretion of
CLL-cells was investigated by immunofixation, but none was
detected in the supernatant of co-cultures in a series of five
experiments (data not shown).
IL-2 in combination with IL-10 exerted strong alterations
in the BMSCs/sCD40L-induced CLL-cell
immunophenotype
IL-2 and IL-10 induced the majority of the investigated adhesion
molecules including CD11c, CD18, CD44, CD49d, and CD54,
whereas the SDF1 receptor CD184 decreased. The B-cell
specific antigens CD19 and CD20, the activation markers
CD23 and CD69, and costimulators for T-cells, like CD40 and
CD86 were also induced. IL-2 and IL-10, however, did not
change the expression of HLA-DR and CD45, but influenced
CD38 heterogeneously among cases (Figure 1d). The extent of
up-regulation of CD23, CD40, CD86 by IL-2 and IL-10 was
much lower than by IL-4 (Figures 1c and d). The pattern and
extent of up-regulation of these antigens were similar in all
cases, and were independent of the proliferation (Supplemen-
tary Figure 1 on Leukemia’s website).
On the mRNA level, the expression of PAX5 was nearly
maintained, whereas CD19, IRF4, and BLIMP1 were
up-regulated by sCD40L in combination with IL-2 and IL-10 in
co-cultured CLL-cells compared with sCD40L alone, but did not
reach significance (Figure 2).
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Figure 2 Transcription analysis of CLL-cells. mRNA from CLL-cells
cultured under different conditions was isolated and analyzed for the
expression of PAX-5 (a), IRF4 (b), BLIMP-1 (c), and CD19 (d) by
TaqMAN gene expression assays. mRNA was quantified as relative
mRNA level and given in arbitrary units relative to 18 s RNA
expression in each case. The contamination by BMSC-mRNA was
ascertained with B0.1% by measuring VCAM-1 expression and was
graded as negligible. Box 1: sorted, peripheral blood CLL-cells, box 2:
CLL-cells on BMSCs, box 3: CLL-cells on BMSCs/sCD40L, box 4: CLL-
cells on BMSCs/sCD40L and IL-4, box 5: CLL-cells on BMSCs/sCD40L
and IL-2/IL-10. Relative mRNA expression levels of 11–12 indepen-
dent experiments are depicted as box and whisker plots. Rings indicate
outliers and triangles indicate extreme outliers. Significance (two-
tailed) is calculated with the paired t-test with *Pp0.05, **Pp0.001.
CLL in a model for pseudofollicles
M Plander et al
2122
Leukemia
CLL-cells from clinically progressive cases were able to
proliferate
The applied staining method with mild fixation and high DNA
accessible DNA dye DAPI hardly influenced the antigen
expression levels and resulted in low spectral overlaps and
small CVs of DNA histograms fulfilling the requirements for
accurate multiparameter DNA analysis.27 No dividing CLL-cells
were detectable in the peripheral blood of the 21 cases studied
(Figure 4a). Neither BMSCs, sCD40L, and IL-4 on their own, nor
their combination induced CLL-cell division in our cultures
(data not shown). To make sure that the missing proliferative
effect of the soluble CD40L is not due to an insufficient
concentration or a lack of functionality of the synthetic
molecules, CLL-cells were stimulated with sCD40L from two
different manufacturers in multiple concentrations (0.5, 1.0, 3.0,
and 5.0 mg/ml). However, we did not detect any proliferation
regardless of the concentration or origin of sCD40L (data not
shown).
In 8 of our 21 cases (Table 1), we could induce cell division of
CLL-cells co-cultured with BMSCs and stimulated by a
combination of sCD40L, IL-2, and IL-10 (Figure 4a).
Interestingly, CLL-cells from all thrombocytopenic cases were
able to proliferate. We could also induce cell division in two
cases with platelet counts around the minimum normal level
(140–166 109/l). None of the patients had isolated thrombo-
cytopenia without other signs of disease progression indicating
autoimmune thrombocytopenia. In all, 6 of 8 patients with
proliferating CLL-cells had an unmutated IgVH region, and 7 of
these 8 patients were also anemic, all of them expressed ZAP-
70, but 3 of them carried hardly any CD38 antigen (Table 1).
The proportion of cells in S and G2/M phase varied between 0.7
and 7.8% at the end of the co-culture period (Figure 4b). The
Figure 3 IRF4 expression in CLL-cells. (a) IRF4 immunohistochemistry of a trephine biopsy from a CLL case with IRF4-positive (brown) cells,
counterstained with hematoxylin (original magnification 20). (b–g) IRF4 immunohistochemistry of cytospin specimens of sorted and cultured
CLL-cells (original magnification 40, f: 100): (b) sorted CLL-cells, (c) CLL-cells on BMSCs, (d) CLL-cells on BMSCs and sCD40L, (e) and (f)
CLL-cells on BMSCs/sCD40L and IL-4, (g) CLL-cells on BMSCs/CD40L and IL-2/ IL-10. Microscope Imager Z1, camera AxioCam MRC, acquisition
software Axiovision Rel 4.6.3, objective lenses: EC Plan Neofluar 20 /0.5, EC Plan Neofluar 40 /1.3 oil, EC Plan Neofluar 100 /1.3 oil (Zeiss),
adobe photoshop for image processing.
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different proliferative responses were not associated with
proliferation of contaminating T cells, because the ratio of
T-lymphocytes remained under 1% at the end of the co-culture
(data not shown). Also, differences in the expression of IL-2Ra
(CD25) were not responsible for different proliferation capacities
as the range of up-regulation varied widely on IL-2 and IL-10
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and did not correlate with proliferative responses (Supplemen-
tary Figure 1 on Leukemia’s website).
The knowledge of a specific proliferation-associated surface
immunophenotype in CLL would be helpful to find small
proliferating populations especially in bone marrow aspirations
and to perform a reliable DNA analysis. To determine the
specific antigen expression pattern of the dividing cell pool, we
gated the S and G2/M phase fraction. Adhesion antigens such as
CD44, CD54, and the integrins CD18, CD11c, and CD49d were
expressed by the proliferating cells at a high level. Furthermore,
co-stimulators for T-cell activation like CD40, HLA-DR, and
B7-2 (CD86) were also intensively expressed. The majority of
proliferating cells carried the low affinity IgE receptor CD23
brighter than the nonproliferating cells (Figure 4c), but,
interestingly, CD69, another activation antigen, was expressed
with the same intensity as the majority of non-cycling cells. By
backgating to FSC/SSC plot and pulse processing, we could
ensure that individually higher antigen expressions on prolifer-
ating cells cannot solely be attributed to differences in cell size.
Unfortunately, the DAPI-gated S-G2/M phase and G0–G1 phase
CLL-cells could not be resolved by the expression of the
investigated surface antigens measured by flow cytometric
analysis as their fluorescence intensities were found in the
range of all cells including G0–G1 phase CLL-cells. Therefore, it
was not possible to gate the cycling population by means of
fluorescence intensities of these antigens (Figure 4c).
CLL-cells have different survival capabilities in medium
Confirming previous apoptosis studies on CLL, we could show
that BMSCs protected CLL-cells from spontaneous apoptosis
in vitro, whereas the majority of CLL-cells died when cultured in
FCS-supplemented medium demonstrated by the larger degree
of DNA cleavage (‘sub-G1’ region) (Figure 5a). BMSCs did not
provide complete protection from apoptosis as the proportion of
living (annexin V-negative) CLL-cells dropped to 40–60%
on average (Figure 5b) during co-culture. In medium, however,
a different survival rate was observed in our sample cohort.
CLL-cells, able to proliferate (P), showed far better survival in
medium than the cells from non-proliferating cases by the end of
the 84 h incubation period (Figures 5b–d).
One group of non-proliferating cases (NP/1) with unmutated
IgVH (Pat 16, 19, 21, 31) and/or peripheral blood lymphocytosis
above 5 104/ml (Pat 13, 27) also showed higher survival rates
in medium (similar to the proliferating cases) than cells from
indolent cases (NP/2) with mutated IgVH and lower lymphocyte
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counts (Pat 12, 14, 15, 18, 22, 30, 32) (Figures 5b–d).
Interestingly, CLL-cells from indolent cases benefited more from
BMSCs than proliferating cases, although this difference was not
statistically significant (Figure 5b).
Soluble CD40L alone, in combination with IL-4 or with IL-2
and IL-10 exerted very heterogeneous, differential effects on the
survival of CLL-cells both on BMSCs and in medium (data for
IL-2 and IL-10 are shown in Supplementary Figure 2 on
Leukemia’s website).
Discussion
In this report, we introduce an in vitro model for proliferation
centers in CLL composed exclusively of primary human cells
(BMSCs and sorted CLL-cells) with/out T-lymphocytic cytokines
(sCD40L, IL-2, IL-10, IL-4) to learn more about the mutual
interactions between these components and find reasons for the
variable clinical courses of CLL. The commercially available
human BMSC lines (e.g. HS-5) immortalized by a lymphotropic
virus did not seem to be ideal for cultivating lymphocytes;
therefore, human BMSCs isolated from several healthy indivi-
duals and human recombinant soluble CD40L were combined
in this culture system.
The immunophenotyping of CLL-cells co-cultured with
BMSCs reflects a strong activation that may enhance the
adhesion of CLL-cells to BMSCs and improve communication
between CLL-cells and T cells.
In normal B cells, simultaneous engagement of IL-4R and
CD40 leads to high levels of IRF4 expression through STAT6 and
NFkB signaling pathways.23 We demonstrated that these
signaling pathways are probably preserved in CLL-cells because
IRF4, and its known targets CD23 and HLA-DR, were strongly
up-regulated by IL-4. Neither sCD40L nor IL-2 combined with
IL-10 influenced significantly the expression of IRF4; therefore,
we assume a possible key role for IL-4 in the induction of IRF4
expression in CLL. Besides HLA-DR, the other IL-4 up-regulated
co-receptors B7-2 (CD86) and CD40 may additionally serve for
the interaction of CLL-cells and T-lymphocytes in vivo.
The transition from B-cell to plasma cell is coordinated by the
elevated expression of IRF4 resulting in an up-regulation of
BLIMP1.28 The plasma cell differentiation process is accom-
panied by the appearance of CD138 after the plasmablastic
stage and with the decrease in the surface antigens CD19,
CD20, and CD45.26 The up-regulation of IRF4 and the down-
regulation of surface CD19, CD20, and CD45 on CLL-cells by
IL-4 in our model may imply the onset of plasma cell
differentiation. This differentiation, however, seems to be
incomplete as the PAX5 expression was maintained, and the
zinc-finger transcription factor BLIMP1, as well as the typical
surface antigens CD38 and CD138, were not induced in
CLL-cells. High CD23 expression indicated the lack of BLIMP1
in IL-4-stimulated CLL-cells, because BLIMP1 represses the
CD23b promoter by physically interacting with IRF4.23 Several
causes could be responsible for the incomplete plasmacytic
maturation of CLL-cells on IL-4 stimulation in this cell-culture
system: the lack of IL-10 stimulation, the permanent sCD40L
induction, the short incubation period17,29,30 and a possible
maturation arrest, being a general feature of neoplastic cells.31
A similar CXCR4 down-regulating effect of IL-4 was recently
shown on human monocytes.32 Lower CXCR4 expression was
identified on lymph node-infiltrating CLL-cells compared with
peripheral blood CLL-cells,33 which may reflect an in vivo IL-4
effect besides the CXCL12-induced receptor endocytosis.34
Bone marrow stromal cells express IL-4R35 and on IL-4
stimulation they up-regulate VCAM1,36 therefore IL-4 may also
exert an indirect effect on CLL-cells through BMSCs. Despite this
fact, the observed changes in immunophenotype and mRNA
expression are most likely due to a direct effect of IL-4, because
some of them were also shown on leukocytes without
BMSCs.15,23,32
Combined IL-2 and IL-10 stimulation induced also a specific
pattern of antigens on CLL-cells: an increased expression of
integrins, hyaluronate receptor (CD44), activation antigens and
co-receptors. The role of integrins and CD44 is undisputable in
CLL: CD18 and CD49d mediate the adhesion to BMSCs.22
CD44 or b-integrins expressing CLLs show diffuse bone marrow
infiltrations or require more frequent therapy.37
The preceding data clearly demonstrate that proliferating
CLL-cells in the peripheral blood, if they exist at all, are under
the sensitivity level of multiparameter flow cytometric DNA
analysis. In contrast to previous reports,7,11 soluble trimeric
CD40L alone did not induce proliferation in our model system,
although different concentrations of two different sCD40L
molecules were applied. We showed that the proliferation
inducing stimulus (IL-2 and IL-10) pushes just a portion of
CLL-cells into proliferation, similar to the effect of CpG-ODN.19
The proliferating cases belonged to the poor prognostic group.
Of interest, a low platelet count indicated most sensitively the
ability of CLL-cells to proliferate. We assume that the prolifera-
tion of CLL-cells leads to stronger bone marrow infiltration
resulting in lower platelet counts and anemia. All available
trephine bone biopsies from the investigated cases displayed
diffuse bone marrow infiltration in support of this theory. The
low rate of induced proliferation (S and G2/M phase cell
fractions fewer than 4% in 7 of 8 cases) was probably due to the
lack of CLL- and T-cell contact.38 Further studies are required to
determine whether proliferative response changes with disease
progression.
The measurement of the proliferating pool in CLL would be
reasonable, because the increase in proliferating fractions
correlates with the biological progression of non-Hodgkin
lymphomas.39 In CLL-infiltrated bone marrow, the proportion
of the dividing population is usually very low; therefore, the
performance of a reliable DNA analysis is not only technically
demanding, but almost impossible. Unfortunately, we did not
manage to identify any proliferation specific surface immuno-
phenotype to simplify the gating of the proliferating pool. The
stronger expression of adhesion antigens and co-receptors may
reveal the capability of the proliferating pool to better interact
with T-lymphocytes. The brighter CD23 expression on cycling
cells can underscore the authenticity of this in vitro cell culture,
as this phenomenon was also described on the larger Ki-67
positive cells within the proliferation centers.8 We suppose that
the observed immunophenotype changes are the result of
regulation rather than selection of low antigen expressing cells
because the proliferating cells express a batch of antigens higher
(e.g. CD40, HLADR, CD18) and others lower (e.g. CD69,
CD184) than the resting cells.
Defective apoptosis is postulated to be the major factor
responsible for the in vivo accumulation of CLL-cells5; therefore,
the survival of CLL-cells was also measured in the present work.
Our results also confirmed the beneficial effect of BMSCs on the
survival of CLL-cells.22 The slightly better survival of the
indolent cells on BMSCs might be due to the maintenance of
higher Bcl-2 expression described in CLL-cells with ‘good
cytogenetics’ as suggested by Jahrsdo¨rfer et al.20 Interestingly,
survival of CLL-cells varied widely in medium: more cells from
each CLL case with inducible proliferation and from those non-
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proliferating cases having germline IgVH or higher peripheral
blood lymphocytosis (P or NP/1) were able to survive in
medium. The recently described higher Bcl-2-associated X
protein (Bax) degradation activity can explain the lower in vitro
apoptosis of poor prognostic CLL cases.40 In contrast to previous
reports, neither CD40 activation alone nor in combination with
IL-4 significantly improved cell survival in vitro regardless of the
presence of BMSCs.12,13,41 This discrepancy may result from the
difference in co-culture systems. To our knowledge, we
incubated for the first time CLL-cells on human BMSCs with
different cytokines. The more exact calculation of surviving cell
fractions may also have influenced the results; we applied a
precise method for the determination of living cells, which
included measurement of absolute cell count and staining of the
apoptotic cells, as opposed to other studies in which only the
viable or apoptotic cell population was stained.12,13,41 Without
the combination of measurement of absolute cell counts and
annexin V/PI staining, cells that have been in early apoptosis at
the beginning of the culture (annexin V-positive but still of
normal cell size) are likely to be neglected because they simply
form debris and are therefore undetectable by the end of the
co-culture. Furthermore, the rather heterogenic effect of IL-4
on CLL behavior was also concluded from a phase I/II IL-4
therapy study.42
In conclusion, our results demonstrate that the poor prog-
nostic CLL can be characterized by its capacity to proliferate in
co-culture with stroma and IL-2 and IL-10 and its better
resistance to apoptosis in the absence of supporting stroma
cells. The inducible proliferation may lead to CLL progression in
the bone marrow, as best indicated by lower platelet counts. The
involvement of mTOR in CLL-cell proliferation was proved43,44
and inhibition of mTOR has recently received attention as a
potential therapeutic agent in CLL.45 Our data may help to
identify which patients might benefit most from a target specific
treatment.
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